Journal Article

DKFZ-2024-01780

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Gemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in atypical teratoid/rhabdoid tumors.

Metselaar, D. S. ; Meel, M. H. ; Goulding, J. R. ; du Chatinier, A. ; Rigamonti, L. ; Waranecki, P. ; Geisemeyer, N.DKFZ* ; de Gooijer, M. C. ; Breur, M. ; Koster, J. ; Veldhuijzen van Zanten, S. E. M. ; Bugiani, M. ; Franke, N. E. ; Reddy, A. ; Wesseling, P. ; Kaspers, G. J. L. ; Hulleman, E.

2024
Elsevier Maryland Heights, MO

This record in other databases:

Please use a persistent id in citations: doi:10.1016/j.xcrm.2024.101700

Abstract: Atypical teratoid/rhabdoid tumors (ATRTs) are highly malignant embryonal tumors of the central nervous system with a dismal prognosis. Using a newly developed and validated patient-derived ATRT culture and xenograft model, alongside a panel of primary ATRT models, we found that ATRTs are selectively sensitive to the nucleoside analog gemcitabine. Gene expression and protein analyses indicate that gemcitabine treatment causes the degradation of sirtuin 1 (SIRT1), resulting in cell death through activation of nuclear factor κB (NF-κB) and p53. Furthermore, we discovered that gemcitabine-induced loss of SIRT1 results in a nucleus-to-cytoplasm translocation of the sonic hedgehog (SHH) signaling activator GLI2, explaining the observed additional gemcitabine sensitivity in SHH-subtype ATRT. Treatment of ATRT xenograft-bearing mice with gemcitabine resulted in a >30% increase in median survival and yielded long-term survivors in two independent patient-derived xenograft models. These findings demonstrate that ATRTs are highly sensitive to gemcitabine treatment and may form part of a future multimodal treatment strategy for ATRTs.

Keyword(s): ATRT ; atypical teratoid/rhabdoid tumor ; gemcitabine ; neuro oncology ; p53 ; patient-derived models ; pediatric oncology ; sirtuin 1 ; therapy development

Note: 2024 Sep 17;5(9):101700

---

Contributing Institute(s):

1. B062 Pädiatrische Neuroonkologie (B062)
2. DKTK HD zentral (HD01)

Research Program(s):

1. 312 - Funktionelle und strukturelle Genomforschung (POF4-312) (POF4-312)

Appears in the scientific report 2024

---

Database coverage:
; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF >= 10 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---